Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methapyrilene is a first-generation ethylenediamine H1-antihistamine and anticholinergic of the pyridine chemical class developed in the early 1950s. It was primarily used for its sedative effects to treat insomnia and as an anti-allergic agent. Methapyrilene acts as a histamine H1 receptor antagonist by interfering with the agonist action of histamine at the H1 receptor, thereby attenuating inflammatory processes such as allergic rhinitis and urticaria. It also exhibits anticholinergic properties. The drug readily crosses the blood-brain barrier and causes significant sedation. Methapyrilene was withdrawn from markets worldwide in 1979 after it was shown to be a potent carcinogen causing liver cancer in animal studies[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methapyrilene.